Compare TWIN & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWIN | PROF |
|---|---|---|
| Founded | 1918 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 238.1M |
| IPO Year | 1994 | 2017 |
| Metric | TWIN | PROF |
|---|---|---|
| Price | $16.87 | $6.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | $12.00 |
| AVG Volume (30 Days) | 28.5K | ★ 256.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ 1.53 | 1.41 |
| Revenue | ★ $340,738,000.00 | $16,098,000.00 |
| Revenue This Year | $10.79 | $92.40 |
| Revenue Next Year | $8.43 | $64.10 |
| P/E Ratio | $10.31 | ★ $4.52 |
| Revenue Growth | 15.45 | ★ 50.73 |
| 52 Week Low | $6.16 | $3.92 |
| 52 Week High | $19.63 | $8.95 |
| Indicator | TWIN | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 58.55 | 54.11 |
| Support Level | $14.72 | $5.75 |
| Resistance Level | $19.16 | $7.08 |
| Average True Range (ATR) | 0.87 | 0.45 |
| MACD | 0.21 | 0.14 |
| Stochastic Oscillator | 83.83 | 78.61 |
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.